TRIANA Biomedicines closes $120M Series B funding round

USA-based TRIANA Biomedicines has announced the successful closing of its oversubscribed $120 million Series B financing round.

TRIANA is a private biotechnology company, headquartered in Lexington, Massachusetts, USA, and focused on building the leading molecular glue discovery platform to inactivate disease targets that are difficult to address with any other modality.

The Series B financing was co-led by Ascenta Capital and Bessemer Venture Partners. New investors included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. TRIANA received continued support from existing founding investors RA Capital Management and Atlas Venture, along with Lightspeed Venture Partners, Pfizer Ventures, and Surveyor Capital (a Citadel company). In association with the Series B financing, Lorence Kim, M.D., from Ascenta Capital, and Andrew Hedin, of Bessemer Venture Partners, will join TRIANA's Board of Directors.